Regulatory captureThe situation where industries or special interests influence the government agencies meant to regulate them, reducing enforcement and shaping policy in their favor. is the process by which government agencies created to regulate an industry end up serving that industry instead. The concept sounds like a conspiracy theory. It is not. It is a structural mechanism with a fifty-year academic pedigree, exposed repeatedly across sectors from aviation to pharmaceuticals to finance. The pattern is consistent: an agency is created with a public interest mandate, the industry it oversees gradually becomes its primary constituency, and the regulations that emerge protect incumbents rather than the public.
George Stigler, a University of Chicago economist, formalized the theory in his 1971 paper “The Theory of Economic Regulation.” His central thesis was blunt: “as a rule, regulation is acquired by the industry and is designed and operated primarily for its benefit.” Before Stigler, the dominant assumption was the public interest model, which held that regulation arose naturally to correct market failures and protect consumers. Stigler argued the opposite: regulation was a product to be bought and sold, and industries were the buyers.
He won a Nobel Prize for this work in 1982. Fifty years later, the mechanisms he described are not only intact but more sophisticated.
How Regulatory Capture Works
Regulatory capture does not require corruption in the criminal sense. It does not require brown envelopes or explicit quid pro quos. It operates through three structural mechanisms that, individually, might seem benign. Together, they tilt the regulatory playing field decisively toward the regulated.
The revolving doorThe movement of personnel between government regulatory agencies and the industries they oversee, creating structural incentives for regulators to favor the companies they may later work for.. Personnel move between regulatory agencies and the industries they oversee. A regulator who knows her next job will be at the company she is currently supervising has a structural incentive, conscious or not, to maintain good relations. A former industry executive who joins a regulatory agency brings expertise, but also relationships, assumptions, and loyalties formed over a career spent maximizing shareholder value. Between 2004 and 2013, more than 1,500 former federal employees moved into lobbying, consulting, or employment for companies they had previously regulated, according to the Project on Government Oversight.
Information asymmetryA situation where one party in a transaction has more or better knowledge than the other, allowing the informed party to gain advantages at the expense of the less informed party.. Industries possess more technical knowledge about their own operations than the agencies tasked with overseeing them. A pharmaceutical company knows more about its drug trial data than the FDA reviewer reading the application. An aircraft manufacturer knows more about its flight control software than the FAA inspector reviewing the certification. This gap forces regulators into dependence on the very entities they are meant to scrutinize, relying on industry-provided data, industry-funded studies, and industry-trained experts to make safety determinations.
Resource disparity and lobbying. Regulated industries are concentrated, well-funded, and highly motivated. The public interest they are regulated to protect is diffuse. A single pharmaceutical company can afford a permanent lobbying operation in Washington; the patients who might be harmed by an insufficiently tested drug cannot. This asymmetry of resources and motivation means industry voices dominate the regulatory conversation by default, not by conspiracy.
The FAA and Boeing: When the Regulator Delegates Its Own Job
The Federal Aviation Administration offers what may be the clearest modern example of regulatory capture in action. Under the Organization Designation Authorization (ODA) program, the FAA delegated significant portions of aircraft certification to manufacturers themselves. Boeing engineers performed design reviews, conformity inspections, and issued airworthiness certificates for new aircraft. The FAA, in effect, outsourced its core function to the company it was supposed to oversee.
During the certification of the Boeing 737 MAX, the FAA “handed nearly complete control to Boeing” as the company raced to finish the plane to compete with the Airbus A320neo, the New York Times reported. Boeing engineers designed a flight control system called the Maneuvering Characteristics Augmentation System (MCAS), which relied on a single angle-of-attack sensor and could repeatedly push the nose of the aircraft down. The FAA certified the aircraft. Two crashes followed: Lion Air Flight 610 in October 2018 and Ethiopian Airlines Flight 302 in March 2019, killing a combined 346 people.
A subsequent House investigation concluded that the crashes were “the horrific culmination of a series of faulty technical assumptions by Boeing’s engineers, a lack of transparency on the part of Boeing’s management, and grossly insufficient oversight by the FAA,” calling it “the pernicious result of regulatory capture.” The Department of Transportation Inspector General confirmed that weaknesses in FAA’s certification and delegation processes had hindered oversight.
The FAA revoked Boeing’s self-certification authority for the 737 MAX in 2019. It partially restored it in September 2025. The aviation safety failures at Muan International Airport in South Korea, where cost-cutting during construction contributed directly to the severity of a crash that killed 179 people, illustrate that the tension between commercial pressure and safety oversight is not unique to the United States.
The FDA: When the Industry Funds the Regulator
The Food and Drug Administration’s relationship with the pharmaceutical industry involves a structural dependency that goes beyond the revolving door. Since the passage of the Prescription Drug User Fee Act (PDUFAPrescription Drug User Fee Act, a 1992 law that allows the FDA to collect fees from pharmaceutical companies to fund drug review processes, creating financial dependence on the regulated industry.) in 1992, the FDA has collected fees from drug manufacturers to fund the drug approval process. By fiscal year 2023, user fees covered 75 percent of the FDA’s drug review program costs, according to data compiled by the National Academies.
The arrangement created a structural problem: the FDA’s primary funder is the industry it regulates. A 2026 analysis from Harvard Law School’s Petrie-Flom Center described the result as “the worst of both worlds,” arguing that the funding structure made the FDA vulnerable to corporate capture while also exposing it to political interference. The majority of policy changes enacted through successive PDUFA reauthorizations have favored industry through decreased regulatory standards, shortened approval timelines, and increased industry involvement in FDA decision-making.
The opioid crisis offers the most devastating illustration. In 1995, the FDA approved Purdue Pharma’s OxyContin with a label that included an extraordinary claim: “Delayed absorption, as provided by OxyContin tablets, is believed to reduce the abuse liability of the drug.” It was the first time the FDA had allowed such a claim for an opioid painkiller. According to the American Medical Association’s Journal of Ethics, Purdue had not conducted clinical studies to support the idea that OxyContin’s formulation actually reduced abuse in real-world conditions. Janet Woodcock, later the FDA’s principal deputy commissioner, acknowledged a “miscalculation about projected harms.”
The revolving door spins visibly at the FDA. A 2018 investigation by Science magazine found that 11 of 16 FDA medical examiners who worked on drug approvals and then left the agency were subsequently employed by or consulted for the companies they had recently regulated. Of 26 FDA reviewers in hematology-oncology who left between 2001 and 2010, 57 percent went to work for the biopharmaceutical industry. Former FDA Commissioner Scott Gottlieb joined Pfizer’s board of directors three months after leaving the agency in 2019, a position that paid more than $330,000 annually.
Wall Street and the SEC: Regulatory Capture Before the Crash
The 2008 financial crisis exposed regulatory capture at the Securities and Exchange Commission on a scale that reshaped global finance. In April 2004, the SEC held a meeting in which the five largest investment banks (Goldman Sachs, Lehman Brothers, Merrill Lynch, Bear Stearns, and Morgan Stanley) successfully lobbied for an exemption from the net capital rule, which had limited the amount of debt these firms could take on. The exemption allowed leverage ratios to climb past 30-to-1. Within four years, three of the five firms had collapsed or been acquired in fire sales.
The revolving door between Goldman Sachs and the federal government became so well known that it earned its own nickname: “Government Sachs.” Former Goldman CEO Henry Paulson served as Treasury Secretary during the crisis. Former Goldman lobbyist Mark Patterson became chief of staff to Treasury Secretary Timothy Geithner. Goldman Sachs alone accumulated approximately 700 years of cumulated public-office experience among its former employees, representing roughly 30 percent of the total for the five largest U.S. commercial banks, according to research published in the Annals of the American Association of Geographers.
The SEC’s own subsequent assessments acknowledged the problem. The undue influence of former SEC officials working for financial firms contributed to a slowdown in investigations following the crisis. The agency that existed to prevent systemic financial risk had been structurally aligned with the institutions generating it.
Why Regulatory Capture Persists
The persistence of regulatory capture is not a mystery. It is a predictable outcome of three features built into the regulatory system itself.
First, expertise is expensive. Government agencies cannot match industry salaries, which means the most knowledgeable people in any regulated field are disproportionately employed by the regulated industry. Agencies either hire from industry (importing its assumptions) or rely on industry data (importing its framing).
Second, public attention is episodic. Citizens pay attention to regulatory agencies after disasters: after planes crash, after financial markets collapse, after an opioid epidemic kills hundreds of thousands. Between crises, the sustained attention comes from the industry itself, which has permanent, professional relationships with the regulators. As the cybernetics researcher Stafford Beer observed, the purpose of a system is what it does, not what it claims to do. A regulatory system that consistently produces industry-friendly outcomes is functioning as designed, regardless of its stated mission.
Third, the cost of capture is distributed while the benefit is concentrated. When the FAA delegates certification to Boeing, the cost is borne by airline passengers in the form of marginally higher risk. The benefit accrues to Boeing in the form of faster certification and lower compliance costs. The passengers do not organize. Boeing does.
This is not unique to American institutions. The pattern appears wherever a regulatory body depends on the industry it oversees for expertise, funding, or personnel. The mechanisms that created the conditions for the Radium Girls to paint watch dials with their lips in the 1920s, with company assurances that the substance was safe, are structurally identical to the mechanisms that allowed OxyContin to reach the market with an unsupported claim about reduced abuse liability.
What Would Reduce Capture
No serious proposal for eliminating regulatory capture exists, because the structural incentives that produce it are deeply embedded. But credible reforms have been proposed and, in some cases, tested.
Cooling-off periods. Extending the time before former regulators can work for regulated industries reduces the immediate financial incentive. Current federal law imposes a one-year cooling-off period for senior officials, but enforcement is inconsistent and the period is widely considered too short. Proposals for five-year periods face industry opposition.
Independent funding. Reducing agencies’ financial dependence on the industries they regulate would address the PDUFA problem at the FDA. This would require Congress to fully fund regulatory agencies from general appropriations, a solution that is straightforward in principle and politically difficult in practice.
Transparency requirements. Mandatory disclosure of meetings between regulators and industry representatives, public access to industry-submitted data, and real-time publication of regulatory decisions would increase the cost of capture by making it visible. Several European regulatory agencies operate under stricter transparency requirements than their American counterparts.
Structural separation. Separating the promotional and safety functions of agencies (the FAA, for example, has historically been mandated both to promote aviation and to regulate its safety) removes a built-in conflict of interest. Congress partially addressed this at the FAA in 1996, but the tension persists in practice.
None of these measures would eliminate regulatory capture. They would raise its cost.
Sources
- George Washington University Regulatory Studies Center: “Let’s Not Forget George Stigler’s Lessons about Regulatory Capture”
- Sam Peltzman, “Stigler’s Theory of Economic Regulation After Fifty Years,” University of Chicago Law & Economics
- U.S. House Committee on Transportation: “The Boeing 737 MAX: Examining the FAA’s Oversight of the Aircraft’s Certification”
- U.S. Department of Transportation Inspector General: FAA Certification of 737 MAX Final Report, February 2021
- Project on Government Oversight: “Corrupted Oversight: The FAA, Boeing, and the 737 Max”
- AMA Journal of Ethics: “How FDA Failures Contributed to the Opioid Crisis,” August 2020
- Harvard Law Petrie-Flom Center: “Worst of Both Worlds: FDA’s Funding Structure, Corporate Capture, and Political Interference,” January 2026
- Science: “FDA’s Revolving Door: Companies Often Hire Agency Staffers Who Managed Their Successful Drug Reviews”
- Annals of the American Association of Geographers: “The Financial Geography of Resilience: A Case Study of Goldman Sachs”
- CEPR VoxEU: “Revolving Doors and Regulatory Capture”
